CD163 and lung adenocarcinoma: In a cohort study involving 262 surgically resected primary human lung adenocarcinomas, Dujaily et al. reported that statins exhibited a dose-dependent effect in reducing the presence of protumorigenic TAMs, characterized by the markers CD68+ CD163+, within both the tumor stroma and parenchyma.43